B-Raf activating mutant cancer cells are more likely to be sensitive to A. Gefitinib B. KRAS...

B-Raf activating mutant cancer cells are more likely to be sensitive to

A. Gefitinib

B. KRAS inhibitor

C. MEK kinase inhibitor

D. all of the above

Solutions

Expert Solution

BRAF is a human gene that encodes the protein called B-Raf, it is a proto-oncogene. Proto-oncogene is a type of gene that appears normal in its normal state, they function normally. But when this gene become mutated, its function get altered, it converted into the oncogene and get involved in tumor and cancer formation.

Mitogen-activated protein kinase (MAPK) pathway is one of the most crucial pathway which control the growth, proliferation, differentiation, migration, and apoptosis. Extracellular signal-regulated kinase (ERK) pathway is one of the most studied MAPK pathway. External factors such as growth factors and mitogens activated the ERK pathway. Epidermal growth factor receptor (EGFR) is the ligand of receptor tyrosine kinases which initiates the cascade of ERK signalling that flows through RAS GTPase, which acts as a molecular on/off switch. Mutations in B-Raf, KRAS affected this signalling pathway by making it hyperactive.

So, MEK kinase inhibitor will be affective against B-Raf mutant cancer cells which will inhibit the continuous stimulation of MAPK or MEK kinase pathway. It will be the most suitable drug for this mutant cancer cell

As it has been observed that the effect of KRAS mutation also same as B-Raf mutant cell, for this reason, KRAS inhibitor will also work against B-Raf mutant cancer cell.

Gefitinib is the inhibitor of epidermal growth factor receptor's (EGFR) tyrosine kinase domain. And EGF is the ligand which activates the MAPK pathway, so if it can inhibit the EFGR tyrosine kinase domain, then it can inhibit the signalling cascade, and in turn the cancer formation. So, this drug will also work against B-Raf mutant cancer cell.

gladiator answered 1 year ago

Next > < Previous

Related Solutions

In the absence of being about to directly detect mutant genes within cancer cells, what types...

In the absence of being about to directly detect mutant genes within cancer cells, what types of observations allow one to infer that cancer is a disease of mutant cells? Provide at least two types of observations.

why are men more likely to have colon cancer than women

Why are developing B cells so much more likely to successfully recombine L chain genes than...

Why are developing B cells so much more likely to successfully recombine L chain genes than H chain genes?

9) Why are developing B cells so much more likely to successfully recombine L chain genes...

9) Why are developing B cells so much more likely to successfully recombine L chain genes than H chain genes?

(i) What is it about a mutant phenotype that classifies the mutation as “temperature-sensitive”?

a) (i) What is it about a mutant phenotype that classifies the mutation as “temperature-sensitive”? (ii) How is this type of phenotype explained by protein behaviour? b) Would the following types of mutations most likely have: severe effects, mild effects, or no effect on protein function? Briefly explain your answers. Note that there may be more than one correct answer, but you need only to give one sensible answer and explain your reasoning. (i) A nonsense mutation occurring in...

You cross a mutant with phenotype 'a b c^+' to a mutant with the phenotype 'a^+b^+c'...

You cross a mutant with phenotype 'a b c^+' to a mutant with the phenotype 'a^+b^+c' and test cross the F1. Given this genetic map, predict the phenotypes observed in the offspring, and the number of each expected in a population of 2500 (show your work). c < 19 m.u. > a <8 m.u. > b

(A) How do cancer cells get the hallmarks/skills of cancer? (B) Do different cancers get the...

(A) How do cancer cells get the hallmarks/skills of cancer? (B) Do different cancers get the hallmarks/skills of cancer in the same way? Why or why not? (C) Do different cancers get the hallmarks/skills of cancer in the same order? Why or why not?

You have two mutant cells, in which the first mutant cell cannot form dimers, and the...

You have two mutant cells, in which the first mutant cell cannot form dimers, and the second mutant cell lacks the kinase function. What would happen if you if you add Receptor tyrosine kinases (RTK-s) signals to these overexpressed cells, when these two mutant cells already have the Receptor tyrosine kinases already, and respond normally to signals in signal transduction. What will happen in terms of signal transduction in these two cells? Will two mutated cells, one with no kinase...

Fatty Acid Degradation a) Cells with decreased glucose 6-phosphate dehydrogenase activity are more sensitive to oxidative...

Fatty Acid Degradation a) Cells with decreased glucose 6-phosphate dehydrogenase activity are more sensitive to oxidative stress because? b) What cellular conditions typically enhance fatty acid degradation? c) What molecule transports fatty acids into the mitochondria? d) Hydroxybutyrate and acetoacetate are both ketone bodies derived during the degradation of fatty acids. How are ketone bodies used by the body?

Cell Cancer: a. In what ways are cancer cells different from normal cells in terms of...

Cell Cancer: a. In what ways are cancer cells different from normal cells in terms of properties and behavior? b. What is the difference between an oncogene and a tumor suppressor gene?

Subjects